Trial Profile

An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diazoxide (Primary)
Indications Prader-Willi syndrome
Focus Adverse reactions; Registrational
Sponsors Soleno Therapeutics

Most Recent Events

20 May 2025 According to a Soleno Therapeutics media release, data from this study presented at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA.
15 May 2025 According to Soleno Therapeutics media release, company will present data from this study at the Pediatric Endocrine Society (PES) Meeting 2025, which is being held May 15-18, in National Harbor, Maryland.
29 Mar 2024 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com